Treatment of non-small cell lung cancer (NSCLC)

Konstantinos Zarogoulidis, Paul Zarogoulidis, Kaid Darwiche, Efimia Boutsikou, Nikolaos Machairiotis, Kosmas Tsakiridis, Nikolaos Katsikogiannis, Ioanna Kougioumtzi, Ilias Karapantzos, Haidong Huang, Dionysios Spyratos


Radical surgery is the standard of care for fit stage I non-small cell lung cancer (NSCLC) patients. Adjuvant treatment should be offered only as part of an investigation trial. Stage II and IIIA adjuvant cisplatin-based chemotherapy remains the gold standard for completely resected NSCLC tumors. Additionally radiotherapy should be offered in patients with N2 lymph nodes. In advanced stage IIIB/IV or inoperable NSCLC pts, a multidisciplinary treatment should be offered consisted of 4 cycles of cisplatin-based chemotherapy plus a 3rd generation cytotoxic agent or a cytostatic (anti-EGFR, anti-VEGFR) drug.